Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mural Oncology plc - Ordinary Shares
(NQ:
MURA
)
3.370
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mural Oncology plc - Ordinary Shares
< Previous
1
2
Next >
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
November 20, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
November 13, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Participate in Two Upcoming Investor Conferences
November 11, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
MURA Stock Earnings: Mural Oncology Reported Results for Q1 2024
May 14, 2024
Mural Oncology just reported results for the first quarter of 2024.
Via
InvestorPlace
MURA Stock Earnings: Mural Oncology Reported Results for Q4 2023
March 26, 2024
Mural Oncology just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 07, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 07, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
October 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 04, 2024
Via
Benzinga
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
September 26, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
September 23, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology to Present at Two Upcoming Investor Conferences
August 27, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
August 23, 2024
Via
Benzinga
MURA Stock Earnings: Mural Oncology Beats EPS for Q2 2024
August 13, 2024
MURA stock results show that Mural Oncology beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
August 13, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
July 31, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
June 05, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
May 23, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
April 09, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Mural Oncology, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.